glp 1 and eye disease Do GLP-1 Medications Cause Problems? Understanding the NAION Risk – Revolution Health & Wellness A Critical Eye on GLP-1

Common sampling problems are discussed in the third edition of this textbook

Studies suggest that up to 25 to 40% of the weight lost during GLP-1 therapy may come from lean mass, primarily skeletal muscle, if active steps are not taken to preserve it [23]

It was too easy

The AngioSafe 1 study, which is also designed to clarify the association between exposure to GLP-1R agonists and diabetic retinopathy through clinical and preclinical study designs found no risk for severe diabetic retinopathy when patients were treated with GLP-1R agonists, and no effect of GLP-1R agonists on angiogenesis ( Diabetic Retinopathy and Glucagon-Like Peptide 1 Agonists Previous studies, including the DCCT, SUSTAIN-6, LEADER and TECOS trials, have linked exposure to incretin-based therapies and other hypoglycemic agents (i.e., insulin , injectable semaglutide, liraglutide , and oral sitagliptin ) to the exacerbation of pre-existing retinopathy (No authors listed, 1998, 1999